fibroblast growth factor receptor 2

Nomenclature: fibroblast growth factor receptor 2

Abbreviated Name: FGFR2

Family: Receptor tyrosine kinases

Annotation status:  image of an orange circle Annotated and awaiting review. Please contact us if you can help with reviewing.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 821 10q25.3-q26 FGFR2 fibroblast growth factor receptor 2
Mouse 1 840 7 Fgfr2 fibroblast growth factor receptor 2
Rat - 841 1q37 Fgfr2 fibroblast growth factor receptor 2
Previous and Unofficial Names
CD332
BEK
CEK3
CFD1
ECT1
JWS
K-SAM
KGFR
TK14
TK25
bacteria-expressed kinase
keratinocyte growth factor receptor
craniofacial dysostosis 1
Jackson-Weiss syndrome
Crouzon syndrome
Pfeiffer syndrome
KGFRTr
Fgfr-2
Fgfr-7
Fgfr7
svs
Bek
Database Links
BRENDA
Ensembl Gene
Entrez Gene
ExplorEnz
GeneCards
GenitoUrinary Development Molecular Anatomy Project
HomoloGene
Human Protein Reference Database
InterPro
KEGG BRITE Hierarchy
KEGG Gene
OMIM
Orphanet Gene
PhosphoSitePlus
RefSeq Nucleotide
RefSeq Protein
TreeFam
UniGene
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Crystal Structure of Tyrosine Phosphorylated Activated FGF Receptor 2 (FGFR2) Kinase Domain in Complex with ATP Analog and Substrate Peptide
PDB Id:  2PVF
Resolution:  1.8Å
Species:  Human
References:  2
Enzyme Reaction
EC Number: 2.7.10.1
Endogenous ligands (Human)
FGF-1 (FGF1, P05230) > FGF-4 (FGF4, P08620), FGF-7 (FGF7, P21781), FGF-9 (FGF9, P31371) > FGF-2 (FGF2, P09038), FGF-6 (FGF6, P10767)  [6]
Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
nintedanib Hs Inhibition 7.43 pIC50 5
pIC50 7.43 (IC50 3.7x10-8 M) [5]
Agonists
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Affinity Units Reference
palifermin Hs Agonist - -
DiscoveRx KINOMEscan® screen
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan
Reference: 3,7

Key to terms and symbols Click column headers to sort
Target used in screen: FGFR2
Ligand Sp. Type Action Affinity Units
PD-173955 Hs Inhibitor Inhibition 7.51 pKd
cediranib Hs Inhibitor Inhibition 7.46 pKd
R406 Hs Inhibitor Inhibition 7.14 pKd
staurosporine Hs Inhibitor Inhibition 7.0 pKd
brivanib Hs Inhibitor Inhibition 6.96 pKd
axitinib Hs Inhibitor Inhibition 6.96 pKd
pazopanib Hs Inhibitor Inhibition 6.68 pKd
PP-242 Hs Inhibitor Inhibition 6.68 pKd
TAE 684 Hs Inhibitor Inhibition 6.6 pKd
dovitinib Hs Inhibitor Inhibition 6.39 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.

http://www.millipore.com/techpublications/tech1/pf3036
http://www.reactionbiology.com/webapps/main/pages/kinase.aspx


Reference: 1,4

Key to terms and symbols Click column headers to sort
Target used in screen: FGFR2/FGFR2
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
staurosporine Hs Inhibitor Inhibition 3.2 1.0 0.0
Cdk1/2 inhibitor III Hs Inhibitor Inhibition 7.4 1.0 -1.0
dovitinib Hs Inhibitor Inhibition 22.0
SU11652 Hs Inhibitor Inhibition 29.3 14.0 3.0
SB 218078 Hs Inhibitor Inhibition 34.1 83.0 78.0
PKR inhibitor Hs Inhibitor Inhibition 37.6 18.0 3.0
vandetanib Hs Inhibitor Inhibition 38.4
pazopanib Hs Inhibitor Inhibition 40.2
K-252a Hs Inhibitor Inhibition 45.4 20.0 2.0
GSK-3beta inhibitor XII Hs Inhibitor Inhibition 46.1 21.0 2.0
Displaying the top 10 most potent ligands  View all ligands in screen »
Clinically-Relevant Mutations and Pathophysiology
Disease:  Apert syndrome
OMIM:  101200
Orphanet:  87
References: 
Mutations not determined
Disease:  Saethre-Chotzen syndrome
OMIM:  101400
Orphanet:  794
References: 
Mutations not determined
Disease:  Crouzon disease
OMIM:  123500
Orphanet:  207
References: 
Mutations not determined
Disease:  Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis
OMIM:  207410
Orphanet:  83
References: 
Mutations not determined
Disease:  Jackson-Weiss syndrome
OMIM:  123150
Orphanet:  1540
References: 
Mutations not determined
Disease:  Lacrimoauriculodentodigital syndrome
OMIM:  149730
Orphanet:  2363
References: 
Mutations not determined
Disease:  Pfeiffer syndrome type 1
OMIM:  101600
Orphanet:  93258
References: 
Mutations not determined
Disease:  Pfeiffer syndrome type 2
OMIM:  101600
Orphanet:  93259
References: 
Mutations not determined
Disease:  Pfeiffer syndrome type 3
OMIM:  101600
Orphanet:  93260
References: 
Mutations not determined
Disease:  Scaphocephaly, maxillary retrusion, and mental retardation
OMIM:  609579
Orphanet:  168624
References: 
Mutations not determined
Disease:  Bent bone dysplasia syndrome
OMIM:  614592
Orphanet:  313855
References: 
Mutations not determined
Disease:  Beare-Stevenson cutis gyrata syndrome
OMIM:  123790
Orphanet:  1555
References: 
Mutations not determined

References

Show »

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol.29 (11): 1039-45. [PMID:22037377]

2. Chen H, Ma J, Li W, Eliseenkova AV, Xu C, Neubert TA, Miller WT, Mohammadi M. (2007) A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol. Cell27 (5): 717-30. [PMID:17803937]

3. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol.29 (11): 1046-51. [PMID:22037378]

4. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem. J.451 (2): 313-28. [PMID:23398362]

5. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J et al.. (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res.68 (12): 4774-82. [PMID:18559524]

6. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M. (1996) Receptor specificity of the fibroblast growth factor family. J. Biol. Chem.271 (25): 15292-7. [PMID:8663044]

7. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem. Biol.17 (11): 1241-9. [PMID:21095574]

How to cite this page

Receptor tyrosine kinases: fibroblast growth factor receptor 2. Last modified on 13/05/2014. Accessed on 03/09/2014. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1809.